Adil Fatakia, MD
Otolaryngology · Marrero, LANPI 1477737914
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $92,844 of the $148,141 with a category attached, or 62.7%. Aerin Medical Inc. accounts for 67.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $65,275 and has fallen 95.8% since, to $2,744 in 2025. Among otolaryngology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $542.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerin Medical Inc.$99K
- Intersect ENT, Inc.$22K
- Spirair, Inc.$15K
- Stryker$7K
- Sanofi$2K
- Medtronic$618
- plus $2K from 20 others
Across 1,185 payments — averaging $19,416 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$16M
- Eli Lilly$2.5M
- Amgen$1.2M
- Braintree Laboratories, Inc.$487K
- AbbVie$425K
- GSK$404K
- plus $2M from 21 others
Across 1 payment — averaging $106,202 each. An ownership or investment interest held by the physician or an immediate family member.
- Spirair, Inc.$106K
What the payments were for
- Consulting fees$92,84463%
- Speaking & faculty fees$27,50019%
- Travel & lodging$14,56510%
- Food & beverage$13,2329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerin Medical Inc. | 112 | $99,224 |
| Intersect ENT, Inc. | 34 | $21,910 |
| Spirair, Inc. | 4 | $14,514 |
| Stryker | 8 | $7,450 |
| Sanofi | 13 | $2,053 |
| Medtronic(2 entities) | 18 | $618 |
| Acclarent, Inc | 16 | $562 |
| Regeneron Healthcare Solutions, Inc. | 17 | $398 |
| Optinose US, Inc. | 11 | $381 |
| GSK | 12 | $191 |
| Arrinex, Inc. | 1 | $160 |
| Itamar Medical Inc | 1 | $97 |
| AstraZeneca | 4 | $77 |
| Pharming Healthcare, Inc. | 4 | $67 |
| AbbVie(2 entities) | 4 | $66 |
| Inspire Medical Systems, Inc. | 1 | $62 |
| Johnson & Johnson | 1 | $60 |
| Cardiovascular Systems Inc. | 1 | $58 |
| Phathom Pharmaceuticals, Inc. | 4 | $56 |
| Olympus America Inc. | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Phadia US Inc. | 1 | $22 |
| Greer Laboratories, Inc. | 1 | $20 |
| Merck | 1 | $15 |
| Amgen | 1 | $15 |
| Cook Medical LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vivaer RF Stylus$51,757
- SeptAlign$29,028
- VivAer$25,348
- RhinAer$25,348
- VIVAER STYLUS$18,881
- RHINAER STYLUS$17,381
- CLARIFIX$7,360
- DUPIXENT$730
- SINUVA$383
- PROPEL$270
- TURBALIGN$230
- ACCLARENT NAVWIRE Sinus Navigation Guidewire$113
How this compares
$148,141 in reported general payments places this provider in the 95th percentile of 218 otolaryngology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 18 | $23,977 |
| Epinephrine | 19 | $2,319 |
| Omeprazole | 200 | $1,810 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 72 | $1,352 |
| Methylprednisolone | 143 | $1,056 |
| Fluticasone Propionate | 53 | $998 |
| Ipratropium Bromide | 40 | $816 |
| Azelastine Hcl | 14 | $639 |
| Ofloxacin | 27 | $492 |
| Pantoprazole Sodium | 25 | $351 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $197 |
| Cephalexin | 28 | $184 |
| Levocetirizine Dihydrochloride | 14 | $181 |
| Azithromycin | 37 | $174 |
| Ciprofloxacin Hcl | 17 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $381 | $23,97718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 218 otolaryngology providers in Louisiana.
Other otolaryngology in Marrero
- Donald GonzalesNew Orleans$351K
- Kevin McLaughlinCovington$186K
- Edward McCoulNew Orleans$92K
- Michael YimShreveport$77K
- Maura CosettiShreveport$64K
- Lizabeth ClarkeNew Iberia$40K
- Henry BarhamBaton Rouge$32K
- Cherie-Ann NathanShreveport$32K
- Jesse DuplechainLafayette$29K
- Rohan WalvekarNew Orleans$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.